Acquisition Opportunity Cerus Endovascular was acquired by Stryker in May 2023, indicating potential alignment with Stryker’s expansive neurovascular portfolio and distribution channels. Sales teams should explore continuity of care opportunities, integration of Cerus products into Stryker’s systems, and possible cross-sell to Stryker’s global customer base.

Early Stage Revenue Current revenue is under $1 million with a small team (11-50 employees), suggesting a growth-phase company with high upside. Targeted outreach for strategic partnerships, co-development agreements, and channel partnerships could accelerate market adoption of Cerus Endovascular devices.

FDA Milestones Recent FDA 510(k) clearance for 027 microcatheters in 2022 demonstrates regulatory progress and product readiness. Leverage this to position Cerus products for hospital adoption, seek reimbursement discussions, and align clinical education initiatives with potential hospital procurement teams.

Clinical Focus Specialization in interventional neuroradiology for intracranial aneurysms suggests opportunities with neurovascular surgeons, interventional radiologists, and academic centers. Develop targeted outreach to key opinion leaders and engage in multi-center studies or CERUS study sponsorships to boost adoption.

Strategic Fit Small-company agility combined with Stryker’s scale presents a unique buy-and-build opportunity for neurovascular devices. Propose collaboration on next-gen delivery systems, leverage Stryker’s distribution, and explore co-marketing and bundled offerings to expand market reach.